Biofrontera reports preliminary revenue for the Q1. The preliminary unaudited revenue of the Company for the Q1 around EUR6.8M. This represents a revenue growth of approximately 46% compared to the previous year period, with pure product sales increasing by around 48%. The increase marks the fourth consecutive quarter-over-quarter revenue growth despite the traditionally weaker Q1. Preliminary unaudited product sales in the U.S. are expected to be approximately EUR5.2M, compared to EUR3.4M in the same period in 2018. Q1 product sales in Germany increased by approximately 72% to EUR1.1M. Revenue generated in the remainder of Europe will be flat at around EUR600,000, compared to the same period last year. This effect is due to the elimination of re-imports within the EU.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.